ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2013
Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.Oncotarget · 2017Pooled it
- Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Oncotarget · 2016Pooled it
- [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Trial
- Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.Current cancer drug targets · 2025Review
- Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.Investigational new drugs · 2023Article
- Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal transduction and targeted therapy · 2021Review
- Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation.Molecular and clinical oncology · 2016Article
- [Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Article
- Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer.OncoTargets and therapy · 2016Article
- Fatal interstitial lung disease associated with icotinib.Journal of thoracic disease · 2014Article
- Icotinib inhibits the invasion of Tca8113 cells via downregulation of nuclear factor κB-mediated matrix metalloproteinase expression.Oncology letters · 2014Article
- Targeted treatment of mutatedLung Cancer (Auckland, N.Z.) · 2014Review
- Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib.OncoTargets and therapy · 2014Review
- [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC).
methodsA total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity.
resultsA total of 89 patients were assessable. In patients treated with icotinib, the overall response rate (RR) was 36.0% (32/89), and the disease control rate (DCR) was 69.7% (62/89). RR and DCR were significantly improved in patients with adenocarcinoma versus non-adenocarcinoma (P<0.05). The symptom improvement rate was 57.3% (51/89), and the main symptoms improved were cough, pain, chest distress, dyspnea, and Eastern Cooperative Oncology Group performance status. The main toxic effects were rash [30/89 (33.7%)] and diarrhea [15/89 (16.9%)]. The level of toxicity was typically low.
conclusionsThe use of icotinib hydrochloride in the treatment of advanced NSCLC is efficacious and safe, and its toxic effects are tolerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.